Bavarian Nordic CEO shows no mercy to competitors as firm continues partner hunt: "If they fail, the value of our program increases"
Bavarian Nordic’s RSV vaccine candidate has been awarded priority status by both the US and EU authorities. That sends a positive signal to potential partners, says CEO Paul Chaplin.
by christian bundgaard, translated by catherine brett
At exactly 8 o’clock this morning, Bavarian Nordic could announce that it had been granted PRIME status by the European Medicines Agency (EMA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg&w=384&q=75)
